Patient Follow Up Articles & Analysis
41 news found
The dose levels that are evaluated in the Phase 1 part of the study are 50x106 (DL1), 110x106 (DL2) and 250x106 (DL3). As of 8 November 2022, 9 patients were enrolled; baseline and safety data for 8 patients were available (n=4 at DL1; n=4 at DL2). 7 patients reached the follow-up period of 28-days and were ...
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. ...
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive and progression-free; ongoing durations of response exceed 12 months and extend ...
“The analysis of the LungFit PRO study in VCAP patients further demonstrates improved efficacy on multiple parameters in the iNO treatment group compared to standard supportive treatment (SST). ...
“With the ISET technology, we were able to effectively extract CTC in higher numbers and from larger DLA volumes, in all cases thus increasing sensitivity for further studies of CTC in NSCLC patients,” said Dr. Menno Tamminga. Davide Brechot, Deputy Director and CTO of Rarecells Diagnostics commented: “Dr. ...
Patients remain in morphological complete remission (CR) with two patients over two years and a third over one year post-transplant, respectively. ...
As of December 2021, data has been entered on 1001 patients with an increase of 130 patient records since 2019. The Worldwide EndoBarrier Registry continues to support a positive benefit:risk profile for patients with type 2 diabetes and/or obesity treated with EndoBarrier. ...
Following this dosing period, patients are followed up through Week 24. ...
ByKalaris
This designation qualifies Mersana for potential incentives, including tax credits for certain trials, exemption from user fees and the potential for seven years of market exclusivity following approval (if granted). “The FDA’s decision to grant orphan drug designation to XMT-2056 for the treatment of gastric cancer is an important recognition of its potential in ...
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally. ...
” Recent Highlights At the Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT) in March 2022, AlloVir reported updated preliminary data from the open-label Phase 2 study assessing the safety and efficacy of posoleucel for multi-virus prevention in high-risk allo-HCT patients. The updated data set, which includes more ...
ByKalaris
Of the 71 patients enrolled in the Pivotal Cohort, 40 patients have been implanted with the alfapump. ...
Visby Medical, Inc. an innovative diagnostic company, today announced its agreement with Urgent Care for Children (UC4C) to offer the company’s new Sexual Health Click Test to patients for the detection of sexually transmitted infections (STIs) in female patients 14 years of age and older. ...
Safety and efficacy will continue to be followed through Week 26. Posoleucel has the potential to fundamentally transform the treatment landscape for allo-HCT by preventing life-threatening viral diseases and infections, either as a prophylactic therapy in high-risk patients or as a preemptive therapy in patients who have already reactivated one ...
ByKalaris
The study analyzed the outcomes for 335 intermediate-risk prostate cancer patients treated with Cesium-131 brachytherapy. Study patients had significant follow-up time. The median follow-up was 5.8 years, with a range of 4 to 8.9 years. The study found both the “favorable” (147 ...
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months. ...
All patients underwent follow-up ureteroscopy with complete response in four patients. ...
Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes. The paper concludes the following: These statistically significant results demonstrate that [L-Dex] screening should be a standard approach for prospective breast cancer-related lymphedema (BCRL) surveillance. ...
In the study, postmenopausal women with 1 to 3 positive nodes and Recurrence Score results of 0 to 25 showed no benefit from chemotherapy after a median of five years of follow-up, meaning they can potentially avoid negative side effects of the treatment. ...
Patients were screened and implanted at 23 centers in the United States, United Kingdom, The Netherlands, and Belgium. ...